Fetuin-A is also an adipokine

Area of Science:

• Metabolic Disorders and Endocrinology
• Adipose Tissue Biology
• Insulin Resistance Mechanisms

Background:

• Fetuin-A (FetA) is traditionally viewed as a hepatokine that negatively impacts insulin signaling.
• Previous research linked FetA to metabolic dysfunction, but its tissue-specific origins in metabolic syndrome were unclear.

Discussion:

• This study investigated FetA's role in metabolic syndrome, independent of diabetes and cardiovascular complications.
• Elevated circulating FetA levels and FetA secretion from subcutaneous adipose tissue were observed in patients with metabolic syndrome.
• High-fat diet and metabolic syndrome models in mice demonstrated increased FetA mRNA and protein expression.

Key Insights:

• Fetuin-A (FetA) is significantly elevated in the circulation and adipose tissue of metabolic syndrome patients.
• Adipose tissue actively secretes FetA, challenging its classical classification solely as a hepatokine.
• Experimental models confirm FetA upregulation in response to high-fat diets and metabolic syndrome conditions.

Outlook:

• Fetuin-A (FetA) should be re-evaluated and considered a significant adipokine contributing to metabolic syndrome.
• Further research into FetA's adipose-derived functions may reveal new therapeutic targets for insulin resistance.
• Understanding FetA's dual role as hepatokine and adipokine is crucial for metabolic disease management.